Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Iván Pérez-Gutiérrez has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Viral immune profiles in multiple sclerosis and HIV co-infection providing insights into antiretroviral treatment-associated immuno-remodeling

    by Stefano Ruberto, Melanie Rojas-Salazar, María I. Domínguez-Mozo, María Núñez-Orantos, Noemi Cabello-Clotet, Vicente Estrada, Jose Reynaldo Homen, Carolina Olmos-Mata, Juncal Pérez-Somarriba Moreno, Javier Rodríguez-Añover, et al.

  • Open Access

    Bacterial Metabolites in the Plasma of Type 1 Diabetes Patients: Acetate Levels Are Elevated and Correlate with Glycated Haemoglobin and Para-Cresol Is Associated with Liver Disturbances and Hypertension

    by Inés Jiménez-Varas, Martín Cuesta-Hernández, María Inmaculada Domínguez-Mozo, Iván Pérez-Gutiérrez, Stefano Ruberto, Esther Palacios, Ana Moreno-Blanco, Rosa Del Campo, María Ángel García-Martínez, Roberto Álvarez-Lafuente

    Type 1 Diabetes (T1D) is thought to result from the interaction of genetic and environmental factors, with different studies highlighting a potential role for the gut microbiota and its metabolites in modulating immune responses and disease development. We hypothesized that patients with T1D exhibited altered levels of circulating bacterial metabolites compared with healthy controls (HC), and that these metabolite profiles were associated with key demographic, clinical, and analytical features of the disease. A total of 91 T1D patients and 58 HC were recruited. Plasma samples were collected and analyzed with gas chromatography coupled to mass spectrometry for the detection of the metabolites: short-chain fatty acids (SCFAs: acetate [AA], propionate [PA], isobutyrate [IBA], butyrate [BA], isovalerate [IVA], valerate [VA], and methyl valerate [MVA]), medium-chain fatty acids (MCFAs: hexanoate [HxA] and heptanoate [HpA]) and para-cresol (p-cresol). We also calculated the ratios between the different SCFAs with AA. T1D patients showed significantly higher circulating AA levels than HC, along with reduced PA/AA and IBA/AA ratios, indicating an altered SCFA profile. SCFA diversity was lower in T1D patients, with reduced detection of BA, and total SCFA levels were increased mainly due to elevated AA. AA levels were higher and SCFA ratios lower in women with T1D compared with healthy women, while p-cresol levels were higher in men with T1D than in healthy men. In T1D patients, AA levels positively correlated with HbA1c, whereas PA/AA, IBA/AA, and BA/AA ratios showed negative correlations, particularly in women. MV/AA and non-AA/AA ratios were inversely associated with glucose levels, again, mainly in women. p-cresol levels correlated positively with age and ferritin and were higher in T1D patients with liver dysfunction or hypertension. Therefore, we can conclude that T1D is associated with a marked alteration in circulating gut-derived metabolites, characterized by increased AA levels, particularly in women, and an imbalance in SCFA ratios that correlates with glycemic control. These findings, together with the associations observed for p-cresol and metabolic comorbidities, support a role for the gut microbiota–host metabolic axis in T1D.

  • Open Access

    Bacterial Metabolites in the Plasma of Type 1 Diabetes Patients: Acetate Levels Are Elevated and Correlate with Glycated Haemoglobin and Para-Cresol Is Associated with Liver Disturbances and Hypertension

    by Inés Jiménez-Varas, Martín Cuesta-Hernández, María Inmaculada Domínguez-Mozo, Iván Pérez-Gutiérrez, Stefano Ruberto, Esther Palacios, Ana Moreno-Blanco, Rosa del Campo, María Ángel García-Martínez, Roberto Alvarez-Lafuente

    INTRODUCTION: While the exact cause of Type 1 Diabetes (T1D) remains unclear, it is widely believed that both genetic and environmental factors contribute to the development of the disease. Recent research has explored the potential role of gut microbiota and its metabolites in modulating immune responses and influencing the development of autoimmune diseases like T1D. With this purpose, we designed a study: 1. to compare the levels of different bacterial metabolites in plasma samples of T1D patients and healthy controls (HC). 2. to correlate the levels of these metabolites with different demographic, clinical and analytical variables collected from the T1D patients. METHODS: A total of 91 T1D patients were recruited. Plasma samples were collected and analyzed with gas chromatography coupled to mass spectrometry for the detection of the metabolites: short-chain fatty acids (SCFA: acetate [AA], propionate [PA], isobutyrate [IBA], butyrate [BA], isovalerate [IVA], valerate [VA] and methyl valerate [MVA]), medium-chain fatty acids (MCFA: hexanoate [HxA] and heptanoate [HpA]) and para-cresol (p-cresol). We also calculated the ratios between the different SCFA with AA. RESULTS: 1. AA levels were significantly higher in T1D patients than in HC (p=0.0009). PA/AA and IBA/AA ratios were significantly higher in HC (p=0.0004 and p=0.0001, respectively). 2. Glycated haemoglobin (HbA1c) was positively correlated with AA levels (p=0.0001; r=0.406) and a significant negative correlation with a rSpearman< -0.3 was found for PA/AA, IBA/AA and BA/AA ratios. 3. p-cresol correlated with Ferritin levels (p=0.04; r=0.362); besides, p-cresol levels were lower in T1D patients with a normal liver profile (p=0.002) and in T1D patients without hypertension (p=0.005). CONCLUSIONS: Serum levels of bacterial metabolites were significantly different in T1D patients. AA levels were significantly increased in T1D patients and p-cresol was higher in T1D patients with liver disturbances and hypertension. To develop strategies to restore gut microbiota health and immune balance could be essential for the control of T1D.